Enterovirus Infections: Clinical Trials

142 trials for Enterovirus Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

120 completed, 7 unknown, 5 withdrawn, 4 terminated. 142 Phase 3, 9 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3142Completed 120, Unknown 7, Withdrawn 5, Terminated 4, Recruiting 3, Active not recruiting 2, Not yet recruiting 1
Phase 29Completed 5, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1

Follow Enterovirus Infections: new trials by email Literature Review of Enterovirus Infections trials Research Report on Enterovirus Infections

Trials (filtered) newest first · largest first

All 142 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of BK1803 in Healthy Infants
BK1803, GOBIK Aqueous Suspension Syringes, Bimmugen® Injection - Pertussis, Diphtheria
Phase 3RecruitingTanabe Pharma Corporation3442026-10-212026-11-12
Protective Efficacy , Immunogenicity and Safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).
Tetravalent Inactivated Enterovirus Vaccine (Vero Cell), Placebo - Hand, Foot, and Mouth Disease(HFMD), Herpangina
Phase 3Not yet recruitingSinovac Biotech Co., Ltd60002026-05-012026-05-28
A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants
nOPV2 - Poliomyelitis
Phase 3RecruitingFidec Corporation7402026-04-302026-09-09
A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series
LBVD, Pentavalent vaccine and Inactivated Polio vaccine - Diphtheria, Tetanus
Phase 2 / Phase 3Active not recruitingLG Chem11862025-05-302026-09-03
Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV
Inactivated hepatitis A vaccine (I-HAV) - Hepatitis A, Hepatitis A Virus
Phase 3Active not recruitingChiang Mai University362025-05-252026-05-22
Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)
bivalent enterovirus vaccine (Vero cell), inactivated, Enterovirus Type 71 Vaccine (Vero Cell), Inactivated - Hand, Foot, and Mouth Disease(HFMD)
Phase 3RecruitingSinovac Biotech Co., Ltd80002024-12-132025-01-01
Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents
Mevac-A vaccine, Havrix 720 Junior - HAV, Hepatitis A
Phase 3CompletedChiang Mai University1202024-04-272025-05-04
A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine
Sabin Strain Inactivated Poliovirus Vaccine - Poliomyelitis, Polio
Phase 3CompletedSinovac Biotech Co., Ltd14422023-05-222025-12-18
A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants
sIPV+bOPV, wIPV+bOPV - Poliomyelitis
Phase 3CompletedBeijing Minhai Biotechnology Co., Ltd3002023-03-082024-12-30
Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants
Eupolio - Poliomyelitis, Vaccine Reaction
Phase 3CompletedLG Chem20012023-01-102025-04-06
To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs
Boryung Hepatitis A Vaccine Pre-Filled Syringe Inj. 0.5 mL, HAVRIX 720 Junior 0.5 mL - Hepatitis A, Hep A
Phase 3UnknownBoryung Biopharma Co., Ltd.1062022-12-012022-11-14
Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine
SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A, SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot B, SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot C - Poliomyelitis
Phase 3CompletedSerum Institute of India Pvt. Ltd.10722022-01-092023-10-23
Study to Evaluate Safety and Immunogenicity of nOPV2 at Different Intervals in Infants
nOPV2 - Poliomyelitis
Phase 3CompletedFidec Corporation9052021-12-162024-08-23
Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio Vaccine
bOPV and nOPV2 - Poliomyelitis
Phase 3WithdrawnFidec Corporation2020-12-012022-01-14
Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants
Experimental vaccine, IPV control vaccine, single-person sIPV control vaccine - Poliomyelitis
Phase 3CompletedSinovac Biotech Co., Ltd15722020-11-052024-04-15
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
Nitazoxanide, Placebo, Vitamin Super B-Complex - Enterovirus, Rhinovirus
Phase 3TerminatedRomark Laboratories L.C.2142020-08-192024-10-17
Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine
Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age, Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age, Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age - Poliomyelitis
Phase 3CompletedSinovac Biotech Co., Ltd13002020-05-112021-08-18
To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years
DTaP-IPV combination vaccine - Diphtheria, Tetanus
Phase 3UnknownBoryung Biopharma Co., Ltd.2492019-12-262020-11-06
Hand, Foot, and Mouth Disease: Could EPs®7630 be a Treatment Option
EPs® 7630 - Hand, Foot, and Mouth Disease
Phase 2 / Phase 3CompletedEskisehir Osmangazi University2402019-06-012024-04-09
Confirmatory Study of BK1310 in Healthy Infants
DPT-IPV-Hib, Hib vaccine, DPT-IPV - Tetanus, Diphtheria
Phase 3CompletedTanabe Pharma Corporation2672019-04-012026-01-06

Showing 20 of 142. Sign in to see all of them.

Narrower conditions

Poliomyelitis (101)  ·  Diphtheria (64)  ·  Tetanus (62)  ·  Whooping Cough (48)  ·  Hepatitis B (45)  ·  Haemophilus Infections (40)  ·  Hepatitis A (21)  ·  Hand, Foot and Mouth Disease (9)  ·  Virus Diseases (8)  ·  Hepatitis (7)  ·  Postpoliomyelitis Syndrome (6)  ·  Bacterial Infections (4)  ·  Digestive System Diseases (4)  ·  Flaviviridae Infections (4)

Broader conditions

Infections (142)  ·  Picornaviridae Infections (138)  ·  RNA Virus Infections (138)  ·  Virus Diseases (134)  ·  Central Nervous System Diseases (108)  ·  Central Nervous System Infections (108)  ·  Nervous System Diseases (108)  ·  Neuroinflammatory Diseases (108)  ·  Myelitis (106)  ·  Neuromuscular Diseases (106)  ·  Spinal Cord Diseases (106)  ·  Bacterial Infections and Mycoses (68)  ·  Gram-Positive Bacterial Infections (66)  ·  Actinomycetales Infections (64)

Interventions

diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (16)  ·  DTaP-IPV-HB-PRP-T vaccine (9)  ·  Diphtheria-Tetanus-acellular Pertussis Vaccines (9)  ·  Poliovirus Vaccine, Inactivated (9)  ·  Heptavalent Pneumococcal Conjugate Vaccine (8)  ·  Pentavac (7)  ·  Tetanus Toxoid (7)  ·  Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (6)  ·  Hepatitis A Vaccines (6)  ·  pentacel (6)  ·  13-valent pneumococcal vaccine (4)  ·  Hepatitis B Vaccines (4)  ·  Hiberix (4)  ·  Chickenpox Vaccine (3)  ·  HibTITER protein, Haemophilus influenzae (3)

Sponsors

GlaxoSmithKline (31)  ·  Sanofi Pasteur, a Sanofi Company (29)  ·  Sinovac Biotech Co., Ltd (11)  ·  Sanofi (9)  ·  Fidec Corporation (5)  ·  Merck Sharp & Dohme LLC (5)  ·  Gilead Sciences (4)  ·  Institute of Medical Biology, Chinese Academy of Medical Sciences (4)  ·  LG Chem (4)  ·  Centers for Disease Control and Prevention (3)  ·  Statens Serum Institut (3)  ·  Beijing Minhai Biotechnology Co., Ltd (2)  ·  Boryung Biopharma Co., Ltd. (2)  ·  Chiang Mai University (2)  ·  MCM Vaccines B.V. (2)

Countries

China (27)  ·  United States (15)  ·  Germany (9)  ·  South Korea (8)  ·  Thailand (8)  ·  France (7)  ·  Bangladesh (5)  ·  Belgium (5)  ·  Philippines (5)  ·  Spain (5)  ·  India (4)  ·  Italy (4)  ·  Japan (4)  ·  Mexico (4)  ·  Colombia (3)

Top investigators

Ingrid Kromann (3)  ·  Yuemei Hu (3)  ·  Zhaojun Mo, Master (3)  ·  Abhijeet Anand, MBBS, MPH (2)  ·  Natchaya Kunanitthaworn, MD (2)  ·  Tavitiya Sudjaritruk, MD, PhD (2)  ·  Acary Souza Bulle Oliveira, MD, PhD (1)  ·  Anne Fiquet, MD (1)  ·  Byeonguk Eun (1)  ·  Changgui Li, PHD (1)

Results publications

PMID 27553375, PMID 26873055, PMID 32273184, PMID 17090650, PMID 19117896, PMID 19952980, PMID 21219984, PMID 21289531, PMID 21334243, PMID 21441781, PMID 21807056, PMID 22001281, PMID 22157567, PMID 22273029, PMID 22349525, PMID 22475857, PMID 22531237, PMID 22691430, PMID 22777096, PMID 22992566, PMID 23726161, PMID 23966556, PMID 24108780, PMID 24571754, PMID 24571755, PMID 24656175, PMID 24720702, PMID 24725238, PMID 24725239, PMID 24964084, PMID 25483566, PMID 25765966, PMID 26280786, PMID 26381232, PMID 26770041, PMID 26837471, PMID 27093164, PMID 27288217, PMID 27510380, PMID 27846055, PMID 27846058, PMID 27879555, PMID 28077584, PMID 28274276, PMID 28548626, PMID 29576304, PMID 30958543, PMID 31703934, PMID 32307307, PMID 32676980

NIH funding

2018 (1)